Related Experiment Videos
Non-Hodgkin's Lymphoma in the Elderly
1Department of Geriatric Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Cancer Control : Journal of the Moffitt Cancer Center
|October 1, 1996
Summary
Elderly patients with non-Hodgkin's lymphoma require optimal treatment, including specific drugs like doxorubicin or mitoxantrone. Further research into drug combinations and purine analogs is crucial for improving outcomes in this population.
Area of Science:
- Oncology
- Geriatric Medicine
Background:
- Non-Hodgkin's lymphoma incidence is rising in the elderly population.
- Suboptimal workup and treatment in elderly patients may negatively impact outcomes.
Purpose of the Study:
- To review key characteristics of non-Hodgkin's lymphoma in the elderly.
- To discuss current and emerging treatment strategies for this demographic.
Main Methods:
- Review of classification and staging systems.
- Examination of pathophysiology and clinical presentation.
- Analysis of treatment strategies and therapeutic options.
Main Results:
- The Working Formulation is the primary classification system.
- Histologic subtypes and stage at presentation are similar to younger patients.
- Doxorubicin or mitoxantrone inclusion is vital for optimal response; purine analogs offer new therapeutic avenues.
Conclusions:
- Advanced age and comorbidities present challenges in controlling non-Hodgkin's lymphoma.
- Enhanced research is needed on drug combinations and novel purine analogs for elderly patients.